Exploristics is delighted to welcome Susan Clement-Davies to the Board as a Non-Executive Director. Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including as Managing Director of Equity Capital Markets at Citigroup Global Markets and Managing Director at Torreya Partners LLC, an investment bank serving companies in the Life Sciences industry. Susan is currently Non-Executive Director and Chair of the Audit Committee of Scancell Holdings plc, an AIM-listed clinical-stage immune-oncology company, and is Advisor to Theolytics, a biotechnology company developing anticancer oncolytic viral therapies. She also holds a position as Non-Executive Director and Chair of the Audit Committee on the Board of Evgen Pharma plc an AIM-listed clinical stage drug development company, and is on the Innovations Advisory Board at Chelsea & Westminster NHS Trust Hospital.
Susan Clement-Davies commented: “It is an exciting time to be joining the Board at Exploristics. Exploristics has already established a strong track record in providing exceptional innovative statistical software and biostatistical services to those seeking to optimise clinical trials. As the industry develops at pace Exploristics is set to transform, at scale, to provide its uniquely targeted technology, in conjunction with the use of real-world and synthetic data, to de-risk and accelerate clinical development trials. I look forward to being part of its exciting future.”
Chris Molloy, Chair of the Board at Exploristics said: “Susan brings a wealth of international experience to the Board at a pivotal time for the company. Our technology and skills are in high demand as the industry recognises the value of better planned clinical trials, and the use of real-world data to do so. We welcome her and input to an exciting future.”
Aiden Flynn, founder and CEO of Exploristics said: “It’s a pleasure to welcome Susan to the team at a pivotal moment of growth for the company. Her wealth of experience in the life sciences sector will bring key insights supporting the direction and performance of the business and its growth strategy. Exploristics now provides exceptional innovative statistical software in addition to biostatistics services and consultancy, with many of our solutions built around our flagship study simulation software, KerusCloud. We are in the process of transforming into a technology enabled services company, offering a uniquely targeted approach to de-risk and accelerate clinical development projects.